In 2004, while pursuing his PhD at the University of Nebraska-Lincoln, Prof. Dr. Özkan Ufuk Nalbantoglu envisioned something far ahead of its time: analysing the human microbiome using artificial intelligence. At that moment, the technology to even generate such data did not yet exist.
Years later, as next-generation sequencing matured, the algorithms Prof. Nalbantoglu had developed were adopted by the Earth Microbiome Project; the world’s largest microbiome initiative. What began as a theoretical study had evolved into a globally recognised scientific infrastructure.
From 2014 onward, Prof. Nalbantoglu pushed the work further; developing algorithms not only to analyse the microbiome, but to modulate it in ways that could directly improve human health. That body of work, refined across more than fifteen years in bioinformatics and microbiome research, became the scientific foundation on which Enbiosis was built.
Assoc. Prof. Omer Ufuk Nalbantoglu
Chief Technical Officer (CTO)
Visionary Leadership
Ömer Özkan is a serial entrepreneur and early-stage investor with an unusual appetite for high-conviction bets in deep-tech and science-led sectors. Over the past decade, he has invested across solar energy, legal technology, education, autonomous systems and healthcare; backing companies that challenge incumbents through technology rather than incrementalism.
The pivotal moment came in 2018, when Özkan met Prof. Nalbantoglu. Struck by the depth of his academic background and the clarity of his long-range vision, Özkan became convinced that the microbiome could redefine how we diagnose and treat disease. Enbiosis was founded in 2019, and from that moment on, Özkan closed every other chapter of his career to dedicate himself to one mission: turning microbiome science into a global health company.
Ömer Özkan
Chief Executive Officer
(CEO)
Ömer Özkan
Chief Executive Officer
(CEO)
the technology
Technology Journey
Enbiosis has evolved in two distinct generations. The first established us as a clinically-validated leader in microbiome-based personalised nutrition.The second is a category-defining leap into Digital Twin & AI-Powered nutraceuticals.
Enbiosis 1.0 is an AI-powered SaaS platform that analyses gut microbiome data and generates personalised nutrition strategies for microbiome modulation. It holistically evaluates the relationship between the trillions of bacteria in the gut and the individual’s general health parameters, then designs an optimal diet strategy to drive each microbiome profile toward a healthier state.
The platform runs on global microbiome data drawn from the nearly 20 countries where Enbiosis is active; tens of thousands of profiles today, growing every day. It is delivered as a cloud-based system that allows partners; hospitals, laboratories, diagnostic centres and wellness clinics; to upload sequencing data and automatically generate individualised microbiome reports.
Clinical validation; peer-reviewed and repeatable
Our scientific approach is led by a multidisciplinary team combining computational modeling with clinical expertise. Dr. Ufuk Nalbantoğlu (CTO) leads our digital twin–based modeling, while Varol Tunalı, MD, PhD, oversees clinical strategy and study management, and Beyza Hilal Ermiş, MSc leads clinical nutrition. This structure is supported by experts in bioinformatics, clinical operations, and data science, enabling the translation of microbiome science into clinically actionable solutions. Our work and technology has been validated by multiple peer-reviewed publications and has been presented at leading international congresses.
Deep learning-enhanced wellness scores: a population-level study on gut microbiome profiling and health prediction.
These are not preprints, not observational white papers, not sponsored retrospective studies. They are randomised controlled trials in respected peer-reviewed journals. Together, they make Enbiosis the only company in microbiome-based nutrition whose technology can be considered a clinically proven treatment tool.
Commercial Footprint
Commercial Footprint
Enbiosis 1.0 has since been deployed by licensed partners in the UK, US, Canada, Latin America, the Middle East and Southeast Asia, with active partnerships in ten countries and thousands of individual reports delivered. The United Kingdom formally recognised Enbiosis as one of the best technology companies across Europe (including Israel); a rare distinction for a microbiome start-up.
The Nutraceutical Formulation Engine
If Enbiosis 1.0 was the best personalised-nutrition platform in the world, Enbiosis 2.0 is a different category altogether. It marks our transition from AI-generated diet recommendations to condition-specific microbiome formulations; ready-to-consume nutraceutical powders designed for a targeted clinical outcome.
Powered by digital twin technology and advanced optimisation algorithms, the 2.0 platform enables targeted interventions across a wide range of chronic conditions. Each formulation is developed through simulated testing inside a virtual replica of the patient’s microbiome, before any real-world application.
Turning the microbiome into therapeutic factory
The digital twin platform
Turning the microbiome into therapeutic factory
Unlike traditional approaches that simply add beneficial microbes to the gut, Enbiosis 2.0 instructs the existing microbiome to manufacture the molecules that the body needs. The gut becomes a programmable bioreactor; producing or suppressing specific metabolites, precisely where they are needed.
Breadth of application
The 2.0 engine can now target more than 100 microbiome-related conditions; including diabetes, psoriasis, dry eye disease, inflammatory bowel disease and Alzheimer’s ;and extends beyond health condition management into enhancing energy, sleep quality, mood and cognitive performance.
Clinical validation: the first results are already remarkable
The first 2.0 clinical study, conducted in dry eye disease, delivered striking results: 100% of patients showed significant improvement, 62% achieved full recovery, and the Enbiosis formulation was 2× more effective than regulatory-approved drugs on the Schirmer test ;the gold-standard clinical measure. Microbiome improvements remained sustained 16 weeks after the intervention ended. The pilot manuscript is currently under journal review, with publication expected in the first half of 2026.
60.7%
improvement in tear production
+6mm
Schirmer test gain
62%
full recovery rate
Clinically Validated · 8-week RCT & 8-week post intervention· n=20
THE PIPELINE
An expanding 2026 clinical pipeline
Through 2026, Enbiosis is running one of the most ambitious clinical programmes in the microbiome space ;a coordinated sequence of randomised trials across multiple body systems, validating the 2.0 platform condition by condition.
Dry Eye Disease ;RCT (130 patients)
placebo-controlled, started February 2026, completes June 2026. Builds on the pilot to clinically strengthen the formulation.
achet-format trial starting April 2026, two-month duration. Designed to enhance the efficacy of existing drugs (current max ~45%); strong pharmaceutical licensing potential.
By the end of 2026, Enbiosis will have produced clinical evidence across eight distinct health-condition areas; extending the platform’s proof-of-concept from a single ocular condition to a full multi-system therapeutic category.
Recognition & Achievements
Enbiosis has been recognised by some of the most respected institutions and programmes in European deep tech and life sciences:
UK Tech Rocketship Awards
Gold Medal · 2024
Awarded by the UK government (Department for Business and Trade) as one of the most promising technology companies from outside the UK ;a flagship programme that effectively opened our UK market entry.
Sanofi
Counrty Winner · 2022
NutraIngredients Europe Awards
Finalist · 2023
The leading European award in the nutraceutical and functional-food industry.
UK Department for International Trade recognition
Enbiosis was named one of the best technology companies across Europe (including Israel) at time of assessment.
Digestive Disease Week & IFM International Conference
invited presentations of the multicentre IBS study, 2023.
Together, these milestones position Enbiosis not as a promising start-up, but as a mature, clinically-validated and globally recognised leader in AI-driven microbiome science.
Where we go from here
Enbiosis was founded on a simple, ambitious thesis: that food, when engineered with the precision of software, can do the work of medicine. With 1.0, we proved the thesis clinically. With 2.0, we turn it into a product category.
We are now partnering with global health brands; in supplements, functional foods and beverages, and medical nutrition; to bring Enbiosis-designed formulations to consumers worldwide.
